• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Akili Reports Third Quarter 2023 Financial Results and Provides Business Update

    11/9/23 4:02:00 PM ET
    $AKLI
    Medical/Dental Instruments
    Health Care
    Get the next $AKLI alert in real time by email

    Reports third quarter total revenues of $702 thousand, representing more than 5x growth over the second quarter of 2023, and positive gross margins of ~60% in the quarter

    Company has filed EndeavorOTC with FDA as an over-the-counter treatment for adults with ADHD

    Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today reported its financial results for the quarter ended September 30, 2023, and provided an update on business progress.

    "We are pleased with early results of our previously-announced strategic shift from a prescription to a non-prescription business model focused on EndeavorOTC. It's clear that there is strong demand from individuals struggling with ADHD, and that they are actively seeking new treatment options. Our direct-to-consumer strategy removes accessibility barriers to this clinically-validated treatment," said Matt Franklin, CEO of Akili. "We've submitted EndeavorOTC for FDA review and authorization as an over-the-counter medical product in the adult ADHD market, and anticipate that these business model changes combined with our new direct-to-consumer marketing efforts will accelerate the path to profitability."

    Business Update

    • On October 30, 2023, Akili submitted a 510(k) application to FDA for EndeavorOTC as an over-the-counter treatment for adults with ADHD. The submission was received by FDA on October 30, 2023 and is currently undergoing technical review by FDA.
      • Pursuant to FDA guidance, Akili is continuing to make EndeavorOTC available over-the-counter, without a prescription, while its submission to FDA is under review.
    • Akili also continues to seek FDA authorization for its EndeavorRx label expansion to include adolescents ages 13-17 with ADHD; this filing was accepted by FDA in May 2023 and remains under review.
      • As disclosed in September 2023, Akili plans to pursue regulatory approval for over-the-counter labeling of both of its treatment products and is planning to submit data to FDA in 2024 to potentially convert its EndeavorRx product to over-the-counter labeling.
    • With respect to Akili's ongoing partnership with Shionogi, the Phase 3 study for pediatric ADHD in Japan, which includes both a randomized phase and a longer term follow-up phase, is expected to be complete by the end of the first quarter of 2024. Shionogi plans to submit the results of this trial for regulatory approval to Japan's Pharmaceuticals and Medical Devices Agency in 2024.
    • Effective October 16, 2023, Akili mutually agreed with TALi Digital Limited to terminate the parties' license, development and commercialization agreement and Akili plans to focus its resources on expanding adoption of its adult non-prescription product.
    • EndeavorOTC metrics in the third quarter of 2023:
      • 176,559 first-time app downloads in the period
      • 7,535 active subscribers, defined as total users with a paid subscription in the period
      • $553 thousand in revenues and $533 thousand in billings (a non-GAAP financial measure defined as EndeavorOTC revenues plus the change in deferred revenue)
      • $93 average revenue per paying user in the period (ARPU), defined as revenues divided by subscribers who paid within the period

    Third Quarter 2023 Financial Highlights

    • Cash position: Cash, cash equivalents, and short-term investments as of September 30, 2023 were $86.3 million.
    • Revenues: Total revenues for the third quarter of 2023 were $702 thousand compared to $114 thousand for the second quarter of 2023, driven by the continued growth of EndeavorOTC in the adult ADHD market.
    • Total billings: Total billings, a non-GAAP financial measure defined as revenues plus the change in deferred revenue, were $699 thousand for the third quarter of 2023, compared to $170 thousand for the second quarter of 2023.
    • Total Operating Expenses: GAAP total operating expenses were $18.8 million for the third quarter of 2023, compared to $15.3 million for the second quarter of 2023, driven by increases in EndeavorOTC marketing-related expenses and severance-related charges associated with the headcount reduction announced in September 2023. Non-GAAP total operating expenses were $14.7 million for the third quarter of 2023, compared to $13.1 million for the second quarter of 2023, driven by an increase in EndeavorOTC marketing-related expenses partially offset by the savings associated with the headcount reduction announced in September 2023.
    • Gross Margins: Total gross margins were ~60% in the third quarter of 2023 compared to ~-32% in the second quarter of 2023, driven by the impact of the June 2023 launch of EndeavorOTC in the adult ADHD market.
    • Net income (loss): GAAP net loss was $15.9 million for the third quarter of 2023, compared to a GAAP net loss of $11.8 million for the second quarter of 2023. Non-GAAP net loss was $13.9 million for the third quarter of 2023, compared to a non-GAAP net loss of $12.6 million for the second quarter of 2023.

    Reiterating Financial Guidance

    • Non-GAAP Total Operating Expenses
      • 2023 Non-GAAP total operating expenses expected to be between $55 million and $60 million, which excludes stock-based compensation expense, an impairment loss on certain assets associated with our sublease and severance and termination-related costs associated with reductions to our workforce
      • 2024 Non-GAAP total operating expenses expected to be between $42 million and $47 million, which excludes stock-based compensation expense
    • Cash Runway
      • Cash, cash equivalents, and short-term investments are expected to be sufficient to fund current and planned operations into the second half of 2025
    • Gross Margins
      • By late 2025, non-prescription business model expected to operate at 60-70% gross margins

    For additional information, please see the tables below, which include a reconciliation of the historical non-GAAP financial measures to GAAP financial measures.

    Webcast and Conference Call

    Akili will host a conference call and webcast today, Thursday, November 9, 2023, at 4:30 p.m. ET. A live audio webcast of the conference call and presentation will be available at www.akiliinteractive.com under Investor Relations, Events & Presentations, along with slides that may be referenced during the call. An archived version of the webcast will be available on the Company's website following the event.

    To access the call, dial 888-259-6580 (toll-free) or +1 206-962-3782 (international) and reference "Akili Third Quarter 2023 Earnings."

    Non-GAAP Financial Measures

    In addition to financial information prepared and presented in accordance with generally accepted accounting principles in the United States (GAAP), this press release includes the following non-GAAP financial measures: total billings on a historical basis, non-GAAP total operating expenses on a historical basis, non-GAAP net loss on a historical basis and non-GAAP total operating expenses on a projected basis. Akili derives these non-GAAP financial measures by excluding or adjusting certain expenses and other items from the respective GAAP financial measure that is most directly comparable to each non-GAAP financial measure. Specifically, total billings is defined as revenues plus the change in deferred revenue during the period; 2022 non-GAAP total operating expenses on a historical basis excludes stock-based compensation expense and transaction costs allocated to earn-out shares; 2023 non-GAAP total operating expenses on a historical basis excludes stock-based compensation expense, an impairment loss on certain assets associated with our sublease and severance and termination-related costs associated with the workforce reductions during the year, and 2023 non-GAAP total operating expenses on a projected basis excludes stock-based compensation expense, an impairment loss on certain assets associated with our sublease and severance and termination-related costs associated with the workforce reductions during the year; 2024 non-GAAP total operating expenses on a projected basis excludes stock-based compensation expense; and non-GAAP net loss excludes transaction costs allocated to earn-out shares, stock-based compensation expense, an impairment loss on certain assets associated with our sublease, severance and termination-related costs associated with the workforce reductions announced during the year, and the change in estimated fair value of earn-out liabilities. Akili's management believes that these non-GAAP financial measures are useful to both management and investors in analyzing its ongoing business and operating performance. Management does not intend the presentation of these non-GAAP financial measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP, but as a complement to provide greater transparency. In addition, these non-GAAP financial measures may differ from similarly-named measures used by other companies. A reconciliation of the historical non-GAAP financial measures to GAAP financial measures is included in the attached financial tables. However, a quantitative reconciliation of projected non-GAAP total operating expenses to projected GAAP operating expenses is not available, nor is the probable significance of such reconciling information, due to Akili's inability to predict with reasonable certainty the amount of future stock-based compensation expense at this time.

    EndeavorOTC Indication and Overview

    EndeavorOTC is a digital therapeutic indicated to improve attention function, ADHD symptoms and quality of life in adults 18 years of age and older with primarily inattentive or combined-type ADHD. EndeavorOTC utilizes the same proprietary technology underlying EndeavorRx, a prescription digital therapeutic indicated to improve attention function in children ages 8-12. EndeavorOTC is available under the U.S. Food and Drug Administration's current Enforcement Policy for Digital Health Devices for Treating Psychiatric Disorders During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency. EndeavorOTC has not been cleared or authorized by the U.S. Food and Drug Administration for its indications. It is recommended that patients speak to their health care provider before starting EndeavorOTC treatment. No serious adverse events have been reported in any of our clinical studies. To learn more, visit EndeavorOTC.com.

    EndeavorRx Indication and Overview

    EndeavorRx is the first-and-only FDA-authorized treatment delivered through a video game experience. EndeavorRx is indicated to improve attention function as measured by computer-based testing in children ages 8 to 12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure Test of Variables of Attention (TOVA®) of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. EndeavorRx is available by prescription only. It is not intended to be used as a stand-alone therapeutic and is not a substitution for a child's medication. The most common side effect observed in children in EndeavorRx's clinical trials was a feeling of frustration, as the game can be quite challenging at times. No serious adverse events were associated with its use. EndeavorRx is recommended to be used for approximately 25 minutes a day, 5 days a week, over initially at least 4 consecutive weeks, or as recommended by your child's health care provider. To learn more about EndeavorRx, please visit EndeavorRx.com.

    About Akili

    Akili is pioneering the development of cognitive treatments through game-changing technologies. Akili's approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device but experienced like entertainment. Akili's platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili's belief that effective medicine can also be fun and engaging, Akili's products are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "prepare," "pursue," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements include, without limitation, statements in this press release related to: our use of the STARS-ADHD-Adult study data in a regulatory submission with FDA to obtain regulatory clearance for our over-the-counter product, EndeavorOTC; our expectation regarding our ability to continue to be able to market EndeavorOTC under the relevant FDA guidance; our expectation regarding our ability to use EndeavorOTC to directly and efficiently engage with adults struggling with attention issues and ADHD; our expectation regarding the potential label expansion for EndeavorRx to include adolescents ages 13-17 with ADHD; our plans to request FDA approval of the conversion of both of our products to over-the-counter labeling and to submit data to FDA in 2024; our expectations regarding our partner Shionogi's plans and timing regarding their Phase 3 trial and regulatory submission in Japan; our expectations regarding our path to profitability; our expectations regarding our FY 2023 and FY 2024 non-GAAP total operating expenses; our expectations regarding our future gross margin percentage; our expectation that our existing cash, cash equivalents, and short-term investments will be sufficient to fund our current and planned operations into the second half of 2025; and our expectations regarding our continued strong demand from individuals struggling with ADHD. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to: our ability to obtain and maintain over-the-counter FDA authorization for EndeavorOTC; our ability to continue to commercialize EndeavorOTC under relevant FDA guidance; our ability to obtain regulatory clearance from FDA for a label expansion for EndeavorRx and then to obtain regulatory clearance from FDA to convert our products to over-the-counter-labeling; our ability to successfully create, and navigate, a new category of medicine and to achieve broad adoption of digital therapeutics among customers and healthcare providers; our ability to continue to advance our clinical development pipeline; our ability to defend our intellectual property and satisfy various FDA and other regulatory requirements in and outside of the United States; the risk of adverse macroeconomic or political changes and a changing regulatory landscape in the highly competitive industry in which we operate; the timing and results expected from our and our partners' clinical trials and our reliance on third parties for certain aspects of our business; our ability to accurately estimate expenses, capital requirements, and needs for additional financing; and other risks identified in our current filings and any subsequent filings made with the Securities and Exchange Commission (SEC). We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof and should not be relied upon as representing our views as of any subsequent date. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

    Akili, Inc.
    Unaudited Condensed Consolidated Balance Sheets
     

    September 30,

    June 30,

    December 31,

     

     

     

    2023

     

     

     

    2023

     

     

     

    2022

     

     

    Assets

    Current assets:

    Cash and cash equivalents

    $

    73,799

     

    $

    56,266

     

    $

    54,097

     

    Restricted cash

     

    305

     

     

    305

     

     

    305

     

    Short-term investments

     

    12,482

     

     

    49,576

     

     

    82,034

     

    Accounts receivable

     

    442

     

     

    84

     

     

    41

     

    Prepaid expenses and other current assets

     

    3,608

     

     

    2,493

     

     

    4,565

     

    Total current assets

     

    90,636

     

     

    108,724

     

     

    141,042

     

    Property and equipment, net

     

    644

     

     

    715

     

     

    919

     

    Operating lease right-of-use asset

     

    1,753

     

     

    1,929

     

     

    2,596

     

    Prepaid expenses and other long-term assets

     

    109

     

     

    95

     

     

    —

     

    Total assets

    $

    93,142

     

    $

    111,463

     

    $

    144,557

     

    Liabilities and stockholders' equity

    Current liabilities:

    Accounts payable

    $

    1,217

     

    $

    1,457

     

    $

    2,681

     

    Accrued expenses and other current liabilities

     

    3,385

     

     

    3,227

     

     

    5,616

     

    Deferred revenue

     

    173

     

     

    176

     

     

    106

     

    Operating lease liability

     

    774

     

     

    791

     

     

    826

     

    Note payable, short term

     

    7,500

     

     

    7,500

     

     

    4,375

     

    Total current liabilities

     

    13,049

     

     

    13,151

     

     

    13,604

     

    Note payable, long term

     

    5,209

     

     

    6,965

     

     

    10,442

     

    Operating lease liability, net of current portion

     

    1,928

     

     

    2,122

     

     

    2,485

     

    Corporate bond, net of bond discount

     

    1,999

     

     

    1,943

     

     

    1,834

     

    Earn-out liabilities

     

    1,841

     

     

    4,297

     

     

    5,513

     

    Other long-term liabilities

     

    22

     

     

    22

     

     

    -

     

    Total liabilities

     

    24,048

     

     

    28,500

     

     

    33,878

     

    Commitments and contingencies

    Stockholders' equity

    Common stock

     

    8

     

     

    8

     

     

    8

     

    Additional paid-in capital

     

    357,720

     

     

    355,738

     

     

    350,980

     

    Accumulated deficit

     

    (288,634

    )

     

    (272,758

    )

     

    (240,288

    )

    Accumulated other comprehensive income (loss)

     

    -

     

     

    (25

    )

     

    (21

    )

    Total stockholders' equity

     

    69,094

     

     

    82,963

     

     

    110,679

     

    Total liabilities and stockholders' equity

    $

    93,142

     

    $

    111,463

     

    $

    144,557

     

    Akili, Inc.
    Unaudited Condensed Consolidated Statements of Operations
     

    Three Months Ended

    September 30,

    Nine Months Ended

    September 30,

    Three Months Ended

    June 30,

     

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

    Revenues

    $

    702

     

    $

    82

     

    $

    929

     

    $

    212

     

    $

    114

     

    Cost of revenues

     

    280

     

     

    123

     

     

    567

     

     

    316

     

     

    150

     

    Gross profit (loss)

     

    422

     

     

    (41

    )

     

    362

     

     

    (104

    )

     

    (36

    )

    Operating expenses:

    Research and development

     

    4,912

     

     

    7,554

     

     

    15,629

     

     

    21,216

     

     

    4,633

     

    Selling, general and administrative

     

    13,936

     

     

    16,911

     

     

    37,595

     

     

    47,250

     

     

    10,648

     

    Total operating expenses

     

    18,848

     

     

    24,465

     

     

    53,224

     

     

    68,466

     

     

    15,281

     

    Operating loss

     

    (18,426

    )

     

    (24,506

    )

     

    (52,862

    )

     

    (68,570

    )

     

    (15,317

    )

    Other income, net

     

    2,550

     

     

    77,742

     

     

    4,516

     

     

    77,421

     

     

    3,558

     

    Net income (loss)

    $

    (15,876

    )

    $

    53,236

     

    $

    (48,346

    )

    $

    8,851

     

    $

    (11,759

    )

     

    Akili, Inc.

    GAAP to Non-GAAP Reconciliation

     

    Three Months Ended

    September 30,

    Nine Months Ended

    September 30,

    Three Months Ended

    June 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

    GAAP Total Operating Expenses

    $

    18,848

     

    $

    24,465

     

    $

    53,224

     

    $

    68,466

     

    $

    15,281

     

    Transaction costs allocated to earn-out shares

     

    -

     

     

    (3,046

    )

     

    -

     

     

    (3,046

    )

     

    -

     

    Stock-based compensation

     

    (1,655

    )

     

    (3,153

    )

     

    (6,251

    )

     

    (7,192

    )

     

    (1,837

    )

    Impairment loss on sublease

     

    -

     

     

    -

     

     

    (384

    )

     

    -

     

     

    (384

    )

    Expenses related to workforce reduction

     

    (2,461

    )

     

    -

     

     

    (4,790

    )

     

    -

     

     

    -

     

    Non-GAAP Total Operating Expenses

    $

    14,732

     

    $

    18,266

     

    $

    41,799

     

    $

    58,228

     

    $

    13,060

     

     

    GAAP Net Income (Loss)

    $

    (15,876

    )

    $

    53,236

     

    $

    (48,346

    )

    $

    8,851

     

    $

    (11,759

    )

    Transaction costs allocated to earn-out shares

     

    -

     

     

    3,046

     

     

    -

     

     

    3,046

     

     

    -

     

    Stock-based compensation

     

    1,655

     

     

    3,153

     

     

    6,251

     

     

    7,192

     

     

    1,837

     

    Impairment loss on sublease

     

    -

     

     

    -

     

     

    384

     

     

    -

     

     

    384

     

    Expenses related to workforce reduction

     

    2,461

     

     

    -

     

     

    4,790

     

     

    -

     

     

    -

     

    Change in estimated fair value for earnout liabilities

     

    (2,128

    )

     

    (77,892

    )

     

    (3,182

    )

     

    (77,892

    )

     

    (3,067

    )

    Non-GAAP Net Loss

    $

    (13,888

    )

    $

    (18,457

    )

    $

    (40,103

    )

    $

    (58,803

    )

    $

    (12,605

    )

     

    Total Revenues

    $

    702

     

    $

    82

     

    $

    929

     

    $

    212

     

    $

    114

     

    Deferred revenue, end of period

     

    173

     

     

    109

     

     

    173

     

     

    109

     

     

    176

     

    Deferred revenue, beginning of period

     

    (176

    )

     

    (109

    )

     

    (106

    )

     

    (96

    )

     

    (120

    )

    Total Billings

    $

    699

     

    $

    82

     

    $

    996

     

    $

    225

     

    $

    170

     

     

    EndeavorOTC Revenues

    $

    553

     

     

    -

     

    $

    558

     

     

    -

     

     

    5

     

    Deferred revenue, end of period

     

    -

     

     

    -

     

     

    -

     

     

    -

     

     

    20

     

    Deferred revenue, beginning of period

     

    (20

    )

     

    -

     

     

    -

     

     

    -

     

     

    -

     

    EndeavorOTC Billings

    $

    533

     

     

    -

     

    $

    558

     

     

    -

     

    $

    25

     

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231109115221/en/

    Get the next $AKLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AKLI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Akili Inc.

      15-12G - Akili, Inc. (0001850266) (Filer)

      7/12/24 5:16:02 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Akili Inc.

      EFFECT - Akili, Inc. (0001850266) (Filer)

      7/10/24 12:15:03 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Akili Inc.

      S-8 POS - Akili, Inc. (0001850266) (Filer)

      7/2/24 10:00:03 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care

    $AKLI
    Financials

    Live finance-specific insights

    See more
    • PureTech Health plc – Half-Year Report

      Strong progress across PureTech's portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and $50 million buyback completed Strong balance sheet with expected operational runway for at least three years Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will be filed on Form 6-K w

      8/28/24 2:01:00 AM ET
      $AKLI
      $BMY
      $PRTC
      $VOR
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results

      Shionogi amendment provides Akili with near-term cash payments and cancellation of debt obligation Company announces exploration of strategic alternatives and associated workforce reduction Company to release first quarter 2024 financial results on May 14, 2024 Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today provided several corporate updates, including an amendment to its strategic distribution agreement with Shionogi & Co., Ltd. ("Shionogi"), a leading global pharmaceutical company. Under the terms of the amended agreement, Shionogi has canceled and forgiven a $5.0 million long-term debt obligation and agreed to make certain payments for SDT-001 (the Japanese, l

      4/30/24 8:00:00 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates

      Plans to disclose Q4/FY 2023 financial results on February 29, 2024; CEO Matthew Franklin to participate in fireside chat at TD Cowen's 44th Annual Healthcare Conference on March 4, 2024 Appointed John Spinale to Board of Directors and Audit Committee; provides update regarding plans for April 17, 2024 Annual Meeting and efforts to regain compliance with Nasdaq rules Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today provided several corporate updates, including that it plans to report fourth quarter and full year 2023 financial results and a business update via press release on Thursday, February 29, 2024 after the market closes. The company will not be hosting an ear

      2/21/24 4:05:00 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care

    $AKLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Akili Inc.

      SC 13D/A - Akili, Inc. (0001850266) (Subject)

      7/9/24 8:05:26 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Akili Inc.

      SC 13D/A - Akili, Inc. (0001850266) (Subject)

      7/5/24 5:36:11 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Akili Inc.

      SC 13G/A - Akili, Inc. (0001850266) (Subject)

      7/5/24 12:05:26 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care

    $AKLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PureTech Health plc – Half-Year Report

      Strong progress across PureTech's portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and $50 million buyback completed Strong balance sheet with expected operational runway for at least three years Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will be filed on Form 6-K w

      8/28/24 2:01:00 AM ET
      $AKLI
      $BMY
      $PRTC
      $VOR
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Virtual Therapeutics Announces Results of Tender Offer to Acquire Akili Interactive

      Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games ("Virtual Therapeutics"), today announced that it has successfully completed the tender offer commenced on June 3, 2024, to acquire all outstanding shares of common stock of Akili, Inc. (NASDAQ:AKLI) ("Akili") for $0.4340 per share (the "Offer Price"). The tender offer expired at one minute after 11:59 p.m. EDT on July 1, 2024 (the "Expiration Date"). As of the Expiration Date, a total of 69,674,538 shares, representing approximately 88.2% of the outstanding shares of common stock of Akili, were validly tendered and not validly withdrawn. The number of shares validly tendered in acc

      7/2/24 7:19:00 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game

      Clinically proven to improve attention function, EndeavorOTCⓇ is the first and only digital therapeutic cleared by FDA as an over-the-counter treatment for adults with ADHD Akili, Inc. (NASDAQ:AKLI), a leading digital therapeutics company, today announced U.S. Food and Drug Administration (FDA) clearance of EndeavorOTCⓇ (AKL-T01) as an over-the-counter treatment for adults with attention-deficit/hyperactivity disorder (ADHD). Delivered through an engaging video game experience, EndeavorOTC is indicated to improve attention function as measured by computer-based testing in men and women with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. EndeavorOTC i

      6/18/24 4:01:00 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care

    $AKLI
    Leadership Updates

    Live Leadership Updates

    See more
    • Akili Announces Leadership Transition

      Co-founder and CEO Eddie Martucci, Ph.D. transitions to role of Board chair; Matt Franklin, president and chief operating officer of Akili, appointed president and chief executive officer Akili, Inc. (NASDAQ:AKLI), a leading digital medicine company, today announced that Eddie Martucci transitioned to the role of Board chair, and Matt Franklin has been appointed to serve as president and CEO of the company and as a member of its board of directors, effective October 5, 2023. Martucci replaces former Board chair, Chamath Palihapitiya, who has resigned from the Board, effective October 4, 2023. The leadership transition follows the company's announcement in September that it plans to shif

      10/6/23 7:00:00 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care

    $AKLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Puretech Health Plc

      4 - Akili, Inc. (0001850266) (Issuer)

      7/8/24 7:42:32 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Large owner Palihapitiya Chamath

      4 - Akili, Inc. (0001850266) (Issuer)

      7/5/24 5:36:39 PM ET
      $AKLI
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Large owner Temasek Holdings (Private) Ltd

      4 - Akili, Inc. (0001850266) (Issuer)

      7/5/24 11:54:03 AM ET
      $AKLI
      Medical/Dental Instruments
      Health Care